
  
    
      
        Introduction_NNP
        In_IN June_NNP 2001_CD ,_, heads_NNS of_IN state_NN and_CC government_NN convened_VBD a_DT United_NNP Nations_NNPS Special_JJ Session_NN on_IN
        HIV_NNP /_NN AIDS_NNP and_CC adopted_VBN unanimously_RB the_DT “ Declaration_NNP of_IN Commitment_NNP on_IN HIV_NNP /_NN AIDS_NNP” [_NN 1_CD ]_NN ._. In_IN
        preparation_NN for_IN that_DT session_NN ,_, Schwartländer_NNP et_CC al_NN ._. published_VBD an_DT estimate_NN of_IN the_DT resource_NN
        needs_VBZ for_IN an_DT expanded_VBN global_JJ response_NN to_TO the_DT epidemic_NN ,_, which_WDT called_VBD for_IN around_IN US_NNP $_$ 10_CD
        billion_CD for_IN the_DT fight_NN against_IN HIV_NNP /_NN AIDS_NNP in_IN 2005_CD [_NN 2_CD ]_NN ._. In_IN 2002_CD ,_, on_IN the_DT occasion_NN of_IN the_DT 14_CD th_NN
        International_NNP AIDS_NNP conference_NN in_IN Barcelona_NNP ,_, Spain_NNP ,_, Stover_NNP et_CC al_NN ._. showed_VBD that_IN such_JJ an_DT
        immediate_JJ and_CC expanded_VBN response_NN in_IN low-_JJ and_CC middle-income_JJ countries_NNS could_MD reverse_VB the_DT
        course_NN of_IN the_DT HIV_NNP /_NN AIDS_NNP epidemic_NN and_CC avert_VB nearly_RB 30_CD million_CD infections_NNS through_IN 2010_CD [_NN 3_CD ]_NN ._.
        Today_NN ,_, more_JJR resources_NNS are_VBP available_JJ for_IN the_DT fight_NN against_IN HIV_NNP than_IN ever_RB before_RB ,_, but_CC global_JJ
        efforts_NNS to_TO confront_VB the_DT epidemic_NN continue_VB to_TO disappoint_VB ._. Worldwide_NNP in_IN 2004_CD ,_, more_JJR people_NNS
        were_VBD living_VBG with_IN HIV_NNP and_CC more_JJR people_NNS died_VBD of_IN AIDS_NNP than_IN in_IN any_DT previous_JJ year_NN [_NN 4_CD ]_NN ._. In_IN
        sub-_NN Saharan_NNP Africa_NNP ,_, home_NN to_TO two-thirds_NNS of_IN all_DT people_NNS living_VBG with_IN HIV_NNP /_NN AIDS_NNP ,_, and_CC three_CD out_IN of_IN
        four_CD people_NNS dying_VBG from_IN AIDS_NNP [_NN 4_CD ]_NN ,_, only_RB one_CD in_IN 50_CD persons_NNS with_IN advanced_JJ disease_NN had_VBD access_NN to_TO
        life-saving_JJ medicines_NNS at_IN the_DT beginning_NN of_IN 2004_CD [_NN 5_CD ]_NN ._.
        The_DT theme_NN of_IN the_DT 15_CD th_NN International_NNP AIDS_NNP Conference_NNP in_IN Bangkok_NNP last_JJ summer_NN was_VBD timely_JJ
        and_CC relevant_JJ ._. “ Access_NNP for_IN All_DT” calls_VBZ for_IN extending_VBG to_TO all_DT of_IN those_DT in_IN need_VBP both_DT sufficient_JJ
        resources_NNS and_CC a_DT set_NN of_IN proven_VBN interventions_NNS to_TO prevent_VB new_JJ infections_NNS and_CC save_VB lives_NNS
        through_IN effective_JJ treatment_NN ._. Recent_JJ developments_NNS in_IN HIV_NNP treatment_NN ,_, with_IN simple_JJ combination_NN
        therapies_NNS priced_VBN at_IN less_JJR than_IN US_NNP $_$ 150_CD per_IN year—unthinkable_JJ just_RB a_DT short_JJ time_NN ago—were_NN a_DT
        major_JJ driver_NN of_IN discussions_NNS during_IN the_DT conference_NN ._. Widespread_NNP access_NN to_TO effective_JJ
        antiretroviral_NN therapy_NN (_( ART_NNP )_) for_IN people_NNS living_VBG with_IN HIV_NNP /_NN AIDS_NNP is_VBZ now_RB conceivable_JJ even_RB in_IN
        countries_NNS with_IN severely_RB limited_JJ resources_NNS ._.
        The_DT World_NNP Health_NNP Organization_NNP and_CC its_PRP$ partners_NNS in_IN the_DT Joint_NNP United_NNP Nations_NNPS Programme_NNP on_IN
        HIV_NNP /_NN AIDS_NNP have_VBP defined_VBN an_DT ambitious_JJ “ 3_CD by_IN 5_CD” target_NN of_IN 3_CD million_CD people_NNS on_IN ART—half_NNP of_IN those_DT
        in_IN most_JJS urgent_JJ need—by_NN the_DT end_NN of_IN 2005_CD ._. The_DT potential_JJ epidemiologic_JJ impact_NN of_IN large-scale_JJ
        roll-out_NN of_IN treatment_NN programs_NNS ,_, however_RB ,_, remains_VBZ uncertain_JJ ._. Experience_NN to_TO date_NN is_VBZ limited_VBN ,_,
        and_CC comes_VBZ mostly_RB from_IN Western_JJ countries_NNS and_CC Brazil_NNP ._. While_IN declines_NNS in_IN AIDS_NNP mortality_NN in_IN the_DT
        industrialized_VBN world_NN have_VBP been_VBN impressive_JJ [_NN 6_CD ,_, 7_CD ,_, 8_CD ]_NN ,_, many_JJ of_IN these_DT success_NN stories_NNS have_VBP been_VBN
        accompanied_VBN by_IN a_DT resurgence_NN in_IN HIV_NNP incidence_NN due_JJ to_TO increasing_VBG risk_NN behavior_NN as_IN emphasis_NN
        shifted_VBN from_IN prevention_NN to_TO treatment_NN in_IN the_DT 1990_CD s_VBZ [_NN 9_CD ,_, 10_CD ,_, 11_CD ]_NN ._. Will_MD the_DT extension_NN of_IN ART_NNP to_TO
        millions_NNS who_WP suffer_VBP from_IN AIDS_NNP in_IN developing_VBG countries_NNS be_VB the_DT long-awaited_JJ breakthrough_NN in_IN
        the_DT response_NN to_TO HIV_NNP ,_, or_CC will_MD the_DT emphasis_NN on_IN treatment_NN detract_VB from_IN prevention_NN efforts_NNS ,_, and_CC
        thus_RB hamper_VB AIDS_NNP control_NN in_IN the_DT medium_NN and_CC long_JJ term_NN ?_. The_DT experience_NN in_IN high-income_JJ
        countries_NNS underscores_VBZ the_DT potential_JJ perils_NNS of_IN failing_VBG to_TO adapt_VB prevention_NN strategies_NNS to_TO an_DT
        environment_NN in_IN which_WDT life-saving_JJ treatment_NN becomes_VBZ available_JJ on_IN a_DT large_JJ scale_NN ;_: however_RB ,_,
        more_RBR favorable_JJ outcomes_NNS in_IN some_DT settings_NNS [_NN 12_CD ,_, 13_CD ]_NN indicate_VBP that_IN rising_VBG risk_NN behavior_NN is_VBZ not_RB
        an_DT inevitable_JJ outcome_NN of_IN increased_VBN treatment_NN access_NN ._.
        In_IN our_PRP$ previous_JJ analysis_NN of_IN the_DT potential_JJ benefits_NNS of_IN a_DT comprehensive_JJ package_NN of_IN
        preventive_JJ interventions_NNS [_NN 3_CD ]_NN ,_, we_PRP noted_VBD that_IN these_DT prevention_NN effects_NNS would_MD be_VB achieved_VBN only_RB
        in_IN the_DT presence_NN of_IN wide-scale_JJ treatment_NN and_CC political_JJ support_NN ._. The_DT two_CD intervening_VBG years_NNS
        have_VBP seen_VBN a_DT dramatic_JJ rise_NN in_IN both_DT momentum_NN and_CC financial_JJ resources_NNS for_IN ART_NNP scale-up_JJ ,_, but_CC
        the_DT potential_JJ epidemiologic_JJ impact_NN of_IN treatment_NN in_IN the_DT context_NN of_IN a_DT broader_JJR strategy_NN for_IN
        HIV_NNP /_NN AIDS_NNP control_NN has_VBZ not_RB yet_RB been_VBN examined_VBN ._. In_IN this_DT paper_NN ,_, we_PRP quantify_VB the_DT opportunities_NNS
        and_CC potential_JJ risks_NNS of_IN large-scale_JJ treatment_NN roll-out_NN ._. The_DT results_NNS of_IN this_DT analysis_NN will_MD be_VB
        informative_JJ for_IN all_DT regions_NNS and_CC countries_NNS ,_, independent_JJ of_IN the_DT level_NN and_CC stage_NN of_IN the_DT
        epidemic_NN ._. However_RB ,_, since_IN three_CD of_IN four_CD deaths_NNS from_IN AIDS_NNP occur_VB in_IN sub-_NN Saharan_NNP Africa_NNP ,_,
        successes_NNS and_CC failures_NNS in_IN rolling_VBG out_RP treatments_NNS immediately_RB will_MD have_VB the_DT most_RBS dramatic_JJ
        effects_NNS in_IN this_DT region_NN ._. We_PRP therefore_RB focus_VBP our_PRP$ analyses_NNS and_CC discussions_NNS in_IN this_DT paper_NN on_IN
        the_DT HIV_NNP epidemics_NNS in_IN sub-_NN Saharan_NNP Africa_NNP
        ._.
      
      
        Methods_NNP
        
          Projections_NNP of_IN HIV_NNP Epidemics_NNP in_IN Sub-_NNP Saharan_NNP Africa_NNP
          Baseline_NNP projections_NNS of_IN HIV_NNP epidemics_NNS in_IN sub-_NN Saharan_NNP Africa_NNP have_VBP been_VBN developed_VBN by_IN the_DT
          Joint_NNP United_NNP Nations_NNPS Programme_NNP on_IN HIV_NNP /_NN AIDS_NNP and_CC the_DT World_NNP Health_NNP Organization_NNP based_VBN on_IN the_DT
          most_RBS current_JJ data_NNS available_JJ ,_, and_CC in_IN collaboration_NN with_IN epidemiologic_JJ experts_NNS and_CC analysts_NNS
          within_IN the_DT countries_NNS assessed_VBD [_NN 4_CD ]_NN ._. These_DT “ business_NN as_IN usual_JJ” forecasts_NNS from_IN 2004_CD to_TO 2020_CD
          are_VBP characterized_VBN by_IN the_DT absence_NN of_IN behavioral_JJ change_NN or_CC ART_NNP scale-up_JJ in_IN future_JJ years_NNS ._.
          Combined_VBN with_IN the_DT natural_JJ dynamics_NNS of_IN the_DT epidemic_NN ,_, these_DT assumptions_NNS result_VBP in_IN a_DT
          relatively_RB stable_JJ HIV_NNP prevalence_NN rate_NN ._.
          To_TO simulate_VBP the_DT effects_NNS of_IN prevention_NN and_CC treatment_NN on_IN HIV_NNP /_NN AIDS_NNP incidence_NN ,_, prevalence_NN ,_,
          and_CC mortality_NN ,_, we_PRP first_RB adapted_VBD the_DT analytic_JJ approach_NN used_VBN in_IN the_DT previously_RB described_VBN
          Goals_NNP model_NN [_NN 3_CD ]_NN to_TO allow_VB explicit_JJ modeling_NN of_IN treatment_NN effects_NNS ,_, and_CC calibrated_VBN the_DT model_NN
          to_TO the_DT baseline_NN projections_NNS for_IN three_CD African_JJ regions_NNS (_( East_NNP ,_, West_NNP /_NN Central_NNP ,_, and_CC Southern_NNP )_)
          (_( see_VB Protocol_NNP S_NNP 1_CD for_IN more_JJR details_NNS )_) ._. In_IN line_NN with_IN the_DT predominant_NN epidemiologic_JJ pattern_NN in_IN
          sub-_NN Saharan_NNP Africa_NNP of_IN HIV_NNP spreading_VBG through_IN heterosexual_NN contact_NN ,_, the_DT model_NN divides_VBZ the_DT
          sexually_RB active_JJ population_NN into_IN five_CD different_JJ interacting_VBG risk_NN groups_NNS :_: single_JJ men_NNS ,_,
          single_JJ women_NNS ,_, married_VBN men_NNS ,_, married_VBN women_NNS ,_, and_CC female_JJ sex_NN workers_NNS ._. In_IN sub-_NN Saharan_NNP Africa_NNP
          HIV_NNP is_VBZ transmitted_VBN via_IN other_JJ modes_NNS at_IN comparatively_RB low_JJ levels_NNS ,_, and_CC these_DT modes_NNS were_VBD
          therefore_RB not_RB considered_VBN in_IN our_PRP$ analyses_NNS ._.
          The_DT model_NN includes_VBZ underlying_VBG regional_JJ demography_NN ,_, acquisition_NN of_IN HIV_NNP and_CC other_JJ
          sexually_RB transmitted_VBD infections_NNS (_( STIs_NNP )_) ,_, progression_NN from_IN HIV_NNP to_TO AIDS_NNP ,_, and_CC progression_NN
          from_IN AIDS_NNP to_TO death_NN ._. Annual_JJ risks_NNS of_IN HIV_NNP infection_NN in_IN each_DT risk_NN group_NN depend_VB on_IN the_DT number_NN
          of_IN partnerships_NNS ,_, the_DT number_NN of_IN sex_NN acts_NNS per_IN partnership_NN ,_, HIV_NNP prevalence_NN among_IN partners_NNS
          and_CC condom_NN use_NN ._. These_DT risks_NNS are_VBP magnified_VBN by_IN the_DT presence_NN of_IN other_JJ STIs_NNP [_NN 14_CD ]_NN and_CC also_RB
          vary_VBP as_IN a_DT function_NN of_IN the_DT time_NN since_IN infection_NN ,_, with_IN the_DT highest_JJS risks_NNS during_IN acute_JJ
          infection_NN ,_, followed_VBN by_IN lower_JJR levels_NNS that_WDT persist_VBP until_IN viral_JJ loads_NNS rise_VBP with_IN the_DT onset_NN of_IN
          clinical_JJ AIDS_NNP [_NN 15_CD ,_, 16_CD ,_, 17_CD ]_NN ._.
          The_DT regional_JJ models_NNS were_VBD calibrated_VBN as_IN follows_VBZ :_: first_JJ ,_, plausible_JJ ranges_NNS were_VBD specified_VBN
          for_IN model_NN parameters_NNS governing_VBG sexual_JJ behavior_NN and_CC biological_JJ factors_NNS (_( e_SYM ._. g_SYM ._. ,_, transmission_NN
          risks_NNS and_CC cofactor_NN effects_NNS of_IN other_JJ STIs_NNP )_) based_VBN on_IN review_NN of_IN published_VBN studies_NNS and_CC survey_NN
          results_NNS ;_: second_JJ ,_, multiple_JJ simulations_NNS were_VBD undertaken_VBN by_IN sampling_VBG values_NNS from_IN each_DT of_IN the_DT
          ranges_NNS and_CC recalculating_VBG the_DT model_NN for_IN each_DT set_NN of_IN sampled_VBN parameter_NN values_NNS ;_: third_JJ ,_, model_NN
          fit_NN was_VBD assessed_VBN by_IN comparing_VBG modeled_VBN prevalence_NN for_IN adult_NN males_NNS and_CC females_NNS separately_RB
          to_TO baseline_NN projections_NNS through_IN 2020_CD ;_: and_CC fourth_JJ ,_, the_DT best-fitting_JJ parameter_NN set_VBN in_IN each_DT
          regional_JJ model_NN was_VBD selected_VBN for_IN the_DT purpose_NN of_IN scenario_NN analysis_NN (_( see_VB Protocol_NNP S_NNP 1_LS )_) ._.
        
        
          Alternative_NNP Scenarios_NNS for_IN Prevention_NNP and_CC Treatment_NNP
          Potential_JJ impacts_NNS of_IN prevention_NN efforts_NNS at_IN a_DT given_VBN coverage_NN level_NN were_VBD based_VBN on_IN
          previously_RB published_VBN estimates_NNS [_NN 3_CD ]_NN for_IN a_DT comprehensive_JJ package_NN of_IN 12_CD interventions_NNS that_WDT
          included_JJ mass_NN media_NNS campaigns_NNS ,_, voluntary_JJ counseling_NN and_CC testing_NN ,_, peer_VBP counseling_NN for_IN sex_NN
          workers_NNS ,_, school-_NN ,_, youth-_NN and_CC workplace-based_JJ programs_NNS ,_, condom_NN promotion_NN and_CC distribution_NN ,_,
          treatment_NN for_IN STIs_NNP ,_, and_CC prevention_NN of_IN mother-to-child_JJ transmission_NN ._. The_DT comprehensive_JJ
          package_NN described_VBN by_IN Stover_NNP and_CC colleagues_NNS also_RB included_VBD interventions_NNS such_JJ as_IN harm_NN
          reduction_NN for_IN injecting_VBG drug_NN users_NNS and_CC peer_VBP outreach_NN for_IN men_NNS who_WP have_VBP sex_NN with_IN men_NNS ,_, which_WDT
          we_PRP have_VBP not_RB modeled_VBN for_IN sub-_NN Saharan_NNP Africa_NNP ._. Impacts_NNP were_VBD captured_VBN in_IN terms_NNS of_IN changes_NNS in_IN
          condom_NN use_NN ,_, sexual_JJ partnerships_NNS ,_, treatment-seeking_JJ for_IN STIs_NNP ,_, and_CC age_NN at_IN first_JJ sex_NN ._. The_DT
          impacts_NNS of_IN treatment_NN included_VBD increased_VBN survival_NN by_IN a_DT median_NN of_IN 3_CD y_NN ,_, reductions_NNS in_IN
          transmission_NN probabilities_NNS given_VBN contact_NN with_IN an_DT infected_JJ partner_NN ,_, and_CC behavior_NN
          change_NN ._.
          We_PRP examined_VBD a_DT range_NN of_IN alternative_JJ scenarios_NNS based_VBN on_IN various_JJ levels_NNS and_CC effectiveness_NN
          of_IN prevention_NN interventions_NNS ,_, with_IN and_CC without_IN successful_JJ attainment_NN of_IN the_DT 3_CD by_IN 5_CD
          treatment_NN target_NN for_IN sub-_NN Saharan_NNP Africa_NNP :_:
          
            Baseline_NNP (_(“ business_NN as_IN usual_JJ” )_) ._.
            Risk_NN behaviors_NNS are_VBP maintained_VBN at_IN current_JJ levels_NNS ,_, and_CC no_DT treatment_NN scale-up_JJ occurs_VBZ ._.
            This_DT is_VBZ simply_RB the_DT baseline_NN scenario_NN that_WDT produces_VBZ a_DT relatively_RB stable_JJ prevalence_NN rate_NN
            over_IN the_DT duration_NN of_IN the_DT projection_NN ,_, with_IN the_DT number_NN of_IN people_NNS living_VBG with_IN HIV_NNP and_CC the_DT
            number_NN of_IN new_JJ infections_NNS rising_VBG slowly_RB over_IN time_NN because_IN of_IN population_NN growth_NN ._.
          
          
            Treatment-centered_NNP response_NN ._.
            In_IN two_CD alternative_JJ scenarios_NNS ,_, the_DT 3_CD by_IN 5_CD target_NN of_IN 50_CD %_NN coverage_NN of_IN those_DT in_IN need_NN of_IN
            treatment_NN by_IN the_DT end_NN of_IN 2005_CD is_VBZ attained_VBN ,_, and_CC scale-up_JJ continues_VBZ to_TO reach_VB 80_CD %_NN ART_NNP
            coverage_NN of_IN those_DT in_IN need_NN by_IN 2010_CD ,_, maintained_VBN at_IN 80_CD %_NN thereafter_RB ._. In_IN an_DT “ optimal_NN ART_NNP
            effects_NNS” scenario_NN ,_, we_PRP assumed_VBD that_DT treatment_NN reduces_VBZ transmissibility_NN by_IN 99_CD %_NN ,_, and_CC that_IN
            those_DT under_JJ treatment_NN have_VBP 50_CD %_NN lower_JJR annual_JJ partnership_NN numbers_NNS and_CC two_CD times_NNS higher_JJR
            condom_NN use_NN than_IN other_JJ adults_NNS ._. With_IN a_DT response_NN that_WDT focuses_VBZ primarily_RB on_IN treatment_NN ,_, it_PRP
            is_VBZ assumed_VBN that_DT behavior_NN in_IN the_DT general_JJ community_NN of_IN infected_JJ and_CC uninfected_JJ adults_NNS is_VBZ
            unchanged_JJ from_IN the_DT baseline_NN ._. In_IN an_DT alternative_NN “ mixed_JJ ART_NNP effects_NNS” scenario_NN ,_, less_RBR
            optimistic_JJ assumptions_NNS were_VBD made_VBN :_: that_DT treatment_NN reduces_VBZ transmissibility_NN only_RB to_TO the_DT
            same_JJ levels_NNS as_IN in_IN asymptomatic_JJ infected_JJ individuals_NNS (_( two-thirds_NNS reduction_NN from_IN no_DT
            treatment_NN )_) ,_, and_CC that_DT behavior_NN in_IN treated_VBN patients_NNS is_VBZ the_DT same_JJ as_IN in_IN other_JJ adults_NNS ._. To_TO
            capture_VB the_DT possibility_NN of_IN behavioral_JJ disinhibition_NN in_IN response_NN to_TO treatment_NN
            availability_NN ,_, we_PRP assumed_VBD that_DT condom_NN use_NN declines_NNS by_IN 10_CD %_NN in_IN both_DT treated_VBN patients_NNS and_CC
            the_DT general_JJ community_NN ,_, with_IN other_JJ behaviors_NNS unchanged_JJ ._. The_DT potential_NN for_IN disinhibition_NN
            is_VBZ suggested_VBN primarily_RB by_IN experience_NN in_IN some_DT developed_VBN countries_NNS ,_, where_WRB condom_NN use_NN
            increased_VBN dramatically_RB in_IN the_DT populations_NNS at_IN highest_JJS risk_NN prior_RB to_TO the_DT introduction_NN of_IN
            ART_NNP but_CC then_RB declined_VBD ;_: the_DT likelihood_NN and_CC magnitude_NN of_IN reductions_NNS in_IN condom_NN use_NN in_IN
            sub-_NN Saharan_NNP Africa_NNP ,_, where_WRB such_JJ prevention-induced_JJ changes_NNS generally_RB are_VBP much_RB less_RBR
            prominent_JJ today_NN ,_, might_MD be_VB questioned_VBN ._. We_PRP therefore_RB considered_VBD in_IN sensitivity_NN analyses_NNS a_DT
            variant_NN of_IN this_DT scenario_NN that_WDT excludes_VBZ disinhibition_NN but_CC preserves_VBZ all_DT other_JJ
            assumptions_NNS ._.
          
          
            Prevention-centered_NNP response_NN ._.
            In_IN the_DT absence_NN of_IN wide_JJ availability_NN of_IN treatment_NN ,_, reflecting_VBG weaker_JJR political_JJ and_CC
            social_JJ support_NN for_IN HIV_NNP control_NN efforts_NNS ,_, we_PRP modeled_VBD a_DT scenario_NN in_IN which_WDT the_DT
            comprehensive_JJ prevention_NN package_NN described_VBD previously_RB [_NN 3_CD ]_NN has_VBZ only_RB partial_JJ
            effectiveness_NN at_IN the_DT population_NN level_NN ,_, and_CC no_DT ART_NNP scale-up_JJ occurs_VBZ ._. As_IN evidence_NN about_IN
            the_DT magnitude_NN of_IN treatment–prevention_NN interactions_NNS remains_VBZ limited_VBN ,_, we_PRP considered_VBD a_DT
            reduction_NN of_IN 50_CD %_NN from_IN the_DT full_JJ impact_NN as_IN a_DT base_NN case_NN and_CC examined_VBD a_DT range_NN of_IN reductions_NNS
            from_IN 25_CD %_NN to_TO 75_CD %_NN in_IN sensitivity_NN analyses_NNS ._.
          
          
            Combined_VBN response_NN ._.
            We_PRP examined_VBD two_CD scenarios_NNS combining_VBG treatment_NN and_CC prevention_NN efforts_NNS ,_, reflecting_VBG
            either_CC optimistic_JJ or_CC pessimistic_JJ possibilities_NNS ._. In_IN the_DT optimistic_JJ scenario_NN ,_, treatment_NN
            strengthens_VBZ prevention_NN efforts_NNS ._. ART_NNP coverage_NN is_VBZ the_DT same_JJ as_IN in_IN the_DT two_CD
            treatment-centered_JJ scenarios_NNS ,_, with_IN optimal_NN assumptions_NNS about_IN treatment_NN impact_NN on_IN
            transmissibility_NN and_CC patient_NN behavior_NN ._. It_PRP is_VBZ assumed_VBN that_IN widespread_JJ availability_NN of_IN
            treatment_NN enables_VBZ the_DT full_JJ impact_NN of_IN prevention_NN efforts_NNS to_TO be_VB attained_VBN as_IN described_VBN by_IN
            Stover_NNP et_CC al_NN ._. [_NN 3_CD ]_NN ._. In_IN a_DT more_RBR pessimistic_JJ scenario_NN ,_, an_DT emphasis_NN on_IN treatment_NN leads_VBZ to_TO
            less_RBR effective_JJ implementation_NN of_IN prevention_NN ._. This_DT scenario_NN includes_VBZ the_DT mixed_JJ
            assumptions_NNS about_IN ART_NNP effects_NNS (_( excluding_VBG disinhibition_NN in_IN the_DT general_JJ community_NN )_) ,_, and_CC
            assumes_VBZ only_RB 25_CD %_NN attainment_NN of_IN the_DT maximum_NN potential_JJ impact_NN of_IN prevention_NN efforts_NNS ._.
            Additional_JJ scenarios_NNS could_MD include_VB pessimistic_JJ assumptions_NNS about_IN limited_JJ ART_NNP
            scale-up_JJ levels_NNS and_CC timing_NN ,_, emergence_NN of_IN large-scale_JJ drug_NN resistance_NN resulting_VBG from_IN low_JJ
            adherence_NN ,_, or_CC other_JJ possible_JJ unintended_JJ outcomes_NNS of_IN wider_JJR treatment_NN ._. Certainly_RB ,_,
            large-scale_JJ treatment_NN efforts_NNS will_MD demand_VB close_VB monitoring_NN of_IN adverse_JJ effects_NNS ._. However_RB ,_,
            experience_NN with_IN treatment_NN programs_NNS in_IN developing_VBG countries_NNS has_VBZ been_VBN encouraging_VBG thus_RB
            far_RB ,_, with_IN reported_JJ adherence_NN levels_NNS that_WDT are_VBP at_IN least_JJS as_RB high_JJ as_IN those_DT in_IN developed_VBN
            countries_NNS [_NN 18_CD ,_, 19_CD ]_NN ._.
          
        
      
      
        Results_NNS
        In_IN the_DT baseline_NN projections_NNS for_IN sub-_NN Saharan_NNP Africa_NNP ,_, the_DT annual_JJ number_NN of_IN new_JJ adult_NN HIV_NNP
        infections_NNS rises_VBZ from_IN 2_CD ._. 4_CD to_TO 3_CD ._. 7_CD million_CD between_IN 2004_CD and_CC 2020_CD ,_, and_CC adult_NN AIDS_NNP mortality_NN
        rises_VBZ from_IN 1_CD ._. 8_CD to_TO 2_CD ._. 6_CD million_CD (_( Figure_NN 1_LS )_) ._. If_IN scale-up_JJ of_IN ART_NNP reaches_VBZ the_DT 3_CD by_IN 5_CD target_NN and_CC
        eventually_RB expands_VBZ to_TO 80_CD %_NN coverage_NN ,_, without_IN any_DT behavior_NN change_NN in_IN the_DT broader_JJR community_NN
        (_( treatment-centered_JJ response_NN /_NN optimal_NN ART_NNP effects_NNS )_) ,_, the_DT annual_JJ number_NN of_IN new_JJ infections_NNS
        could_MD be_VB reduced_VBN by_IN up_IN to_TO 6_CD %_NN compared_VBN to_TO baseline_NN by_IN 2020_CD ._. Mortality_NNP would_MD initially_RB
        decline_VB by_IN 33_CD %_NN but_CC long-term_JJ trends_NNS would_MD converge_NN toward_IN the_DT baseline_NN ._. We_PRP note_VBP that_IN total_JJ
        annual_JJ death_NN numbers_NNS indicate_VBP broad_JJ trends_NNS in_IN mortality_NN but_CC mask_NN more_RBR subtle_JJ health_NN gains_NNS
        in_IN the_DT form_NN of_IN years_NNS added_VBD to_TO individuals_NNS '_POS lives_NNS ._.
        With_IN less_RBR optimistic_JJ assumptions_NNS (_( treatment-centered_JJ response_NN /_NN mixed_JJ ART_NNP effects_NNS )_) ,_, the_DT
        number_NN of_IN new_JJ infections_NNS rises_VBZ ,_, to_TO 4_CD ._. 3_CD million_CD per_IN year_NN by_IN 2020_CD (_( a_DT 14_CD %_NN increase_NN )_) ;_: mortality_NN
        trends_NNS are_VBP similar_JJ to_TO the_DT optimistic_JJ scenario_NN in_IN the_DT short_JJ term_NN ,_, but_CC worse_JJR in_IN the_DT long_JJ
        term_NN ,_, even_RB compared_VBN to_TO the_DT baseline_NN ._. Excluding_VBG the_DT assumption_NN of_IN reduced_VBN condom_NN use_NN through_IN
        disinhibition_NN from_IN the_DT treatment-centered_JJ /_NN mixed_JJ effects_NNS scenario_NN has_VBZ minimal_JJ effect_NN on_IN the_DT
        results_NNS ,_, lowering_VBG the_DT number_NN of_IN new_JJ infections_NNS in_IN 2020_CD by_IN only_RB 2_CD %_NN compared_VBN to_TO the_DT scenario_NN
        that_WDT includes_VBZ disinhibition_NN ._.
        A_DT prevention-centered_JJ response_NN would_MD have_VB greater_JJR impact_NN on_IN the_DT number_NN of_IN new_JJ
        infections_NNS ,_, lowering_VBG annual_JJ incidence_NN by_IN more_JJR than_IN half_NN by_IN 2020_CD ._. The_DT long-term_JJ mortality_NN
        trend_NN is_VBZ more_RBR favorable_JJ in_IN the_DT prevention-centered_JJ scenario_NN than_IN in_IN the_DT treatment-centered_JJ
        scenario_NN because_IN of_IN reduced_VBN incidence_NN ,_, but_CC prevention_NN would_MD produce_VB negligible_JJ mortality_NN
        benefits_NNS in_IN the_DT near-_NN and_CC mid-term_JJ future_NN in_IN comparison_NN to_TO strategies_NNS that_WDT include_VBP ART_NNP ._.
        Alternative_NNP assumptions_NNS regarding_VBG overall_JJ effectiveness_NN in_IN a_DT prevention-centered_JJ response_NN
        produce_NN results_NNS that_WDT scale_NN as_IN expected_VBN ,_, with_IN reductions_NNS in_IN annual_JJ incidence_NN of_IN 34_CD %_NN to_TO 64_CD %_NN
        and_CC reductions_NNS in_IN annual_JJ mortality_NN of_IN 20_CD %_NN to_TO 42_CD %_NN by_IN 2020_CD ._.
        If_IN treatment_NN and_CC effective_JJ prevention_NN are_VBP scaled_VBN up_RP jointly_RB in_IN a_DT combined_VBN response_NN ,_, the_DT
        benefits_NNS in_IN terms_NNS of_IN both_DT infections_NNS and_CC deaths_NNS averted_VBN could_MD be_VB substantially_RB higher_JJR ._. In_IN
        an_DT optimistic_JJ scenario_NN in_IN which_WDT treatment_NN programs_NNS support_VBP expanded_VBD prevention_NN ,_, the_DT annual_JJ
        number_NN of_IN new_JJ infections_NNS would_MD be_VB 74_CD %_NN lower_JJR and_CC annual_JJ mortality_NN would_MD be_VB 47_CD %_NN lower_JJR by_IN
        2020_CD ,_, compared_VBN to_TO baseline_NN ._. It_PRP is_VBZ worth_JJ noting_VBG that_IN the_DT long-term_JJ decline_NN in_IN AIDS_NNP deaths_NNS is_VBZ
        driven_VBN more_JJR by_IN prevention_NN of_IN new_JJ infections_NNS than_IN by_IN direct_JJ survivorship_NN benefits_NNS from_IN ART_NNP ._.
        In_IN a_DT pessimistic_JJ scenario_NN in_IN which_WDT a_DT more_RBR narrow_JJ treatment_NN focus_NN limits_NNS effective_JJ
        prevention_NN ,_, the_DT overall_JJ benefits_NNS are_VBP much_RB more_RBR modest_JJ ,_, with_IN 26_CD %_NN and_CC 16_CD %_NN reductions_NNS ,_,
        respectively_RB ,_, in_IN new_JJ infections_NNS and_CC mortality_NN by_IN 2020_CD compared_VBN to_TO the_DT baseline_NN ._.
        Prevalence_NNP rises_VBZ by_IN 7_CD %_NN in_IN the_DT optimal_NN and_CC by_IN 27_CD %_NN in_IN the_DT mixed_JJ treatment-centered_JJ
        scenarios_NNS by_IN 2020_CD ,_, as_IN longer_JJR survival_NN for_IN treated_VBN patients_NNS offsets_NNS reductions_NNS in_IN new_JJ
        infections_NNS through_IN reduced_VBN transmissibility_NN (_( and_CC risk_NN reductions_NNS among_IN treated_VBN patients_NNS in_IN
        the_DT more_RBR optimistic_JJ scenario_NN )_) (_( Figure_NNP S_NNP 1_LS )_) ._. In_IN scenarios_NNS that_WDT include_VBP prevention_NN efforts_NNS ,_,
        prevalence_NN declines_NNS by_IN 41_CD %_NN in_IN the_DT prevention-centered_JJ scenario_NN ,_, by_IN 53_CD %_NN in_IN the_DT optimistic_JJ
        combined_VBN response_NN ,_, and_CC by_IN 6_CD %_NN in_IN the_DT pessimistic_JJ combined_VBN response_NN by_IN 2020_CD ._.
        The_DT total_JJ number_NN of_IN infections_NNS averted_VBN through_IN a_DT combined_VBN response_NN would_MD be_VB 29_CD million_CD
        over_IN the_DT period_NN 2004_CD to_TO 2020_CD if_IN treatment_NN enhances_VBZ prevention_NN ,_, a_DT benefit_NN that_WDT is_VBZ ten_CD times_NNS
        greater_JJR than_IN that_DT of_IN a_DT strategy_NN which_WDT focuses_VBZ on_IN treatment_NN only_RB ,_, even_RB with_IN optimal_NN
        assumptions_NNS ,_, and_CC 51_CD %_NN greater_JJR than_IN that_DT of_IN a_DT strategy_NN which_WDT focuses_VBZ on_IN (_( less_RBR effective_JJ )_)
        prevention_NN alone_RB (_( Table_NNP 1_LS )_) ._. If_IN a_DT treatment_NN focus_NN limits_NNS the_DT effectiveness_NN of_IN prevention_NN ,_, on_IN
        the_DT other_JJ hand_NN ,_, the_DT total_JJ number_NN of_IN averted_VBN infections_NNS between_IN 2004_CD and_CC 2020_CD would_MD be_VB 9_CD
        million_CD ._. Similarly_RB ,_, the_DT benefits_NNS of_IN a_DT combined_VBN response_NN in_IN terms_NNS of_IN mortality_NN reductions_NNS
        are_VBP considerably_RB higher_JJR under_IN optimistic_JJ circumstances_NNS than_IN the_DT benefits_NNS of_IN either_DT
        treatment_NN only_RB or_CC prevention_NN only_RB ,_, with_IN 10_CD ._. 1_LS million_CD deaths_NNS averted_VBN (_( 27_CD %_NN )_) through_IN 2020_CD when_WRB
        treatment_NN enhances_VBZ prevention_NN ,_, compared_VBN to_TO 5_CD ._. 0_CD million_CD (_( 13_CD %_NN )_) in_IN the_DT optimal-effects_JJ
        treatment_NN only_RB scenario_NN ,_, 3_CD ._. 5_CD million_CD (_( 9_CD %_NN )_) in_IN the_DT mixed-effects_JJ treatment_NN only_RB scenario_NN ,_, and_CC
        4_CD ._. 8_CD million_CD (_( 13_CD %_NN )_) with_IN prevention_NN only_RB ._. Under_IN more_RBR pessimistic_JJ assumptions_NNS about_IN
        treatment–prevention_NN interactions_NNS ,_, the_DT combined_VBN response_NN would_MD avert_VB 5_CD ._. 8_CD million_CD deaths_NNS
        (_( 16_CD %_NN )_) ._. Table_NNP 1_CD also_RB reports_VBZ total_JJ benefits_NNS of_IN the_DT various_JJ strategies_NNS over_IN the_DT shorter_JJR term_NN ,_,
        in_IN which_WDT the_DT ranking_NN of_IN alternatives_NNS is_VBZ similar_JJ with_IN regard_NN to_TO the_DT total_JJ number_NN of_IN
        infections_NNS averted_VBN ,_, but_CC mortality_NN reductions_NNS are_VBP attributable_JJ almost_RB exclusively_RB to_TO
        treatment_NN ._.
        Combining_NNP treatment_NN with_IN prevention_NN efforts_NNS will_MD reduce_VB the_DT resource_NN needs_VBZ for_IN treatment_NN
        substantially_RB in_IN the_DT long_JJ term_NN (_( Figure_NN 2_LS )_) ._. In_IN the_DT various_JJ scenarios_NNS the_DT numbers_NNS of_IN people_NNS
        being_VBG treated_VBN in_IN 2020_CD ranges_NNS from_IN 9_CD ._. 2_CD million_CD in_IN the_DT treatment_NN only_RB (_( mixed_JJ effects_NNS )_)
        scenario_NN ,_, to_TO 4_CD ._. 2_CD million_CD in_IN the_DT optimistic_JJ combined_VBN response_NN scenario_NN ._.
      
      
        Discussion_NNP
        In_IN this_DT paper_NN ,_, we_PRP have_VBP examined_VBN the_DT potential_JJ epidemiologic_JJ impact_NN of_IN global_JJ HIV_NNP /_NN AIDS_NNP
        control_NN efforts_NNS under_IN a_DT range_NN of_IN alternative_JJ scenarios_NNS reflecting_VBG varying_VBG implementation_NN of_IN
        strategies_NNS for_IN prevention_NN and_CC treatment_NN ._. Although_IN we_PRP focus_VBP in_IN particular_JJ on_IN population_NN
        health_NN outcomes_NNS and_CC epidemiologic_JJ trends_NNS ,_, we_PRP recognize_VBP that_IN there_EX are_VBP numerous_JJ other_JJ
        social_JJ ,_, economic_JJ ,_, and_CC individual_JJ health_NN effects_NNS of_IN interventions_NNS including_VBG ART_NNP that_WDT are_VBP
        beyond_IN the_DT scope_NN of_IN this_DT analysis_NN ._. We_PRP also_RB restrict_VBP our_PRP$ focus_NN in_IN this_DT paper_NN to_TO sub-_NN Saharan_NNP
        Africa_NNP ,_, where_WRB the_DT overwhelming_JJ majority_NN of_IN people_NNS living_VBG with_IN and_CC dying_VBG from_IN HIV_NNP /_NN AIDS_NNP
        reside_VB ;_: however_RB ,_, our_PRP$ findings_NNS have_VBP broader_JJR applicability_NN and_CC more_RBR general_JJ implications_NNS in_IN
        the_DT worldwide_NN fight_NN against_IN HIV_NNP /_NN AIDS_NNP ,_, which_WDT we_PRP highlight_VB here_RB ._.
        
          The_DT Potential_JJ for_IN Treatment_NNP to_TO Enhance_NNP Prevention_NNP Must_MD Be_VB Exploited_NNP
          Effective_NNP prevention_NN requires_VBZ more_JJR than_IN having_VBG sufficient_JJ funds_NNS to_TO offer_VB information_NN
          and_CC services_NNS ._. It_PRP also_RB requires_VBZ an_DT environment_NN that_WDT encourages_VBZ people_NNS to_TO internalize_NN
          messages_NNS about_IN risky_JJ behavior_NN and_CC to_TO adopt_VB actual_JJ behavior_NN change_NN ,_, and_CC allows_VBZ people_NNS to_TO
          utilize_VB services_NNS such_JJ as_IN testing_NN and_CC counseling_NN without_IN fear_NN of_IN stigma_NN or_CC discrimination_NN ._.
          Stoneburner_NNP and_CC Low-_NNP Beer_NNP have_VBP argued_VBN that_IN the_DT supportive_JJ social_JJ and_CC political_JJ environment_NN
          in_IN Uganda_NNP allowed_VBD people_NNS to_TO discuss_VB AIDS_NNP with_IN family_NN members_NNS and_CC close_VB friends_NNS ,_, which_WDT led_VBD
          to_TO greater_JJR behavior_NN change_NN than_IN in_IN Kenya_NNP or_CC Zambia_NNP where_WRB most_JJS people_NNS received_VBD information_NN
          from_IN mass_NN media_NNS only_RB [_NN 20_CD ]_NN ._. People_NNS have_VBP little_JJ reason_NN to_TO seek_VB HIV_NNP testing_NN when_WRB a_DT positive_JJ
          result_NN brings_VBZ only_RB negative_JJ consequences_NNS ,_, whereas_IN widespread_JJ availability_NN of_IN treatment_NN
          provides_VBZ a_DT major_JJ incentive_NN for_IN people_NNS to_TO learn_VB their_PRP$ serostatus_JJ ._.
          Involving_NNP communities_NNS and_CC family_NN members_NNS in_IN the_DT delivery_NN of_IN treatment—for_NN example_NN ,_, as_IN
          treatment_NN monitors—offers_NNS unique_JJ entry_NN points_NNS for_IN effective_JJ prevention_NN activities_NNS and_CC a_DT
          lever_NN for_IN population-wide_JJ behavior_NN change_NN ._. Experience_NN with_IN community_NN roll-out_NN of_IN
          treatment_NN programs_NNS has_VBZ shown_VBN ,_, for_IN example_NN ,_, that_DT uptake_NN of_IN voluntary_JJ counseling_NN and_CC
          testing_NN increased_VBD by_IN 300_CD %_NN in_IN one_CD year_NN of_IN roll-out_NN in_IN Haiti_NNP ,_, and_CC by_IN a_DT factor_NN of_IN 12_CD in_IN
          Khayelitsha_NNP ,_, South_NNP Africa_NNP ,_, after_IN treatment_NN introduction_NN [_NN 21_CD ,_, 22_CD ]_NN ._. A_DT study_NN targeting_VBG nine_CD
          commuter_NN sites_NNS in_IN South_NNP Africa_NNP found_VBD the_DT highest_JJS levels_NNS of_IN condom_NN use_NN ,_, willingness_NN to_TO use_VB
          a_DT female_JJ condom_NN ,_, and_CC willingness_NN to_TO have_VB an_DT HIV_NNP test_NN in_IN Khayelitsha_NNP ,_, a_DT difference_NN that_WDT
          may_MD be_VB attributed_VBN largely_RB to_TO the_DT availability_NN of_IN ART_NNP and_CC comprehensive_JJ AIDS_NNP care_NN [_NN 23_CD ]_NN ._. If_IN
          increased_VBN uptake_NN of_IN voluntary_JJ counseling_NN and_CC testing_NN is_VBZ indicative_JJ of_IN broader_JJR prevention_NN
          effectiveness_NN where_WRB ART_NNP is_VBZ available_JJ ,_, we_PRP estimate_VBP that_IN over_IN 50_CD %_NN more_RBR new_JJ infections_NNS and_CC
          more_RBR than_IN twice_RB as_IN many_JJ deaths_NNS could_MD be_VB avoided_VBN through_IN a_DT combined_VBN response_NN compared_VBN to_TO
          prevention_NN alone_RB ._. In_IN contrast_NN ,_, if_IN a_DT narrow_JJ treatment_NN scale-up_JJ leads_VBZ to_TO reduced_VBN
          effectiveness_NN of_IN prevention_NN ,_, short-term_JJ mortality_NN reductions_NNS will_MD come_VB at_IN the_DT expense_NN of_IN
          longer-term_JJ progress_NN in_IN stemming_VBG the_DT tide_NN of_IN the_DT epidemic_NN ._.
          During_IN most_JJS of_IN the_DT past_JJ 15_CD years_NNS ,_, efforts_NNS to_TO address_VB the_DT AIDS_NNP epidemic_NN in_IN sub-_NN Saharan_NNP
          Africa_NNP have_VBP focused_VBN on_IN prevention_NN ._. There_EX have_VBP been_VBN successes_NNS in_IN some_DT countries_NNS ,_, but_CC
          overall_JJ these_DT efforts_NNS have_VBP not_RB achieved_VBN their_PRP$ goals_NNS ._. The_DT advent_NN of_IN vastly_RB expanding_VBG
          treatment_NN programs_NNS in_IN the_DT coming_VBG years_NNS ,_, if_IN opportunities_NNS to_TO capitalize_VB on_IN broadened_VBD
          political_JJ support_NN and_CC community_NN mobilization_NN can_MD be_VB seized_VBN ,_, offers_VBZ the_DT potential_NN to_TO
          enhance_VB prevention_NN effectiveness_NN and_CC avert_VB many_JJ new_JJ infections_NNS and_CC deaths_NNS ._.
        
        
          Only_RB Effective_NNP Prevention_NNP Will_NNP Make_NNP Treatment_NNP Affordable_NNP in_IN the_DT Long_NNP Run_NNP
          While_IN prevention_NN programs_NNS are_VBP unlikely_JJ to_TO achieve_VB full_JJ impact_NN in_IN the_DT absence_NN of_IN
          treatment_NN ,_, so_RB too_RB is_VBZ the_DT impact_NN of_IN treatment_NN programs_NNS reduced_VBN if_IN vigorous_JJ prevention_NN
          efforts_NNS are_VBP absent_JJ ._. Without_IN effective_JJ prevention_NN ,_, the_DT number_NN of_IN people_NNS requiring_VBG care_NN and_CC
          treatment_NN will_MD grow_VB each_DT year_NN ._. As_IN more_JJR and_CC more_JJR people_NNS are_VBP kept_VBN alive_JJ with_IN ART_NNP the_DT
          treatment_NN burden_NN will_MD become_VB enormous_JJ unless_IN effective_JJ prevention_NN reduces_VBZ the_DT number_NN of_IN
          people_NNS becoming_VBG newly_RB infected_JJ ._.
          Without_IN effective_JJ prevention_NN programs_NNS ,_, we_PRP project_VBP that_IN the_DT number_NN of_IN people_NNS receiving_VBG
          treatment_NN will_MD grow_VB to_TO 6_CD ._. 3_CD million_CD by_IN 2010_CD and_CC up_IN to_TO 9_CD ._. 2_CD million_CD by_IN 2020_CD in_IN Africa_NNP alone_RB
          to_TO achieve_VB 80_CD %_NN coverage_NN of_IN those_DT in_IN urgent_JJ need_VBP ._. Meeting_VBG this_DT need_VBP would_MD require_VB a_DT
          tremendous_JJ increase_NN in_IN financing_NN ,_, human_JJ capacity_NN and_CC infrastructure_NN that_WDT might_MD not_RB be_VB
          attainable_JJ ._.
          If_IN effective_JJ prevention_NN programs_NNS are_VBP combined_VBN with_IN treatment_NN programs_NNS ,_, the_DT same_JJ level_NN
          of_IN 80_CD %_NN ART_NNP coverage_NN would_MD be_VB achieved_VBN by_IN treating_VBG 5_CD ._. 8_CD million_CD in_IN 2010_CD and_CC 4_CD ._. 2_CD million_CD in_IN
          2020_CD ._. In_IN other_JJ words_NNS ,_, the_DT same_JJ goal_NN could_MD be_VB attained_VBN at_IN a_DT far_RB lower_JJR treatment_NN cost_NN and_CC
          with_IN a_DT much_RB greater_JJR chance_NN of_IN sustainability_NN ._.
        
        
          A_DT Successful_JJ Global_NNP Response_NNP Cannot_NNP Rely_NNP on_IN Either_DT Prevention_NNP or_CC Treatment_NNP
          Alone_NNP
          Over_IN the_DT long_JJ term_NN ,_, it_PRP is_VBZ effective_JJ prevention_NN that_WDT will_MD reduce_VB the_DT burden_NN of_IN illness_NN
          due_JJ to_TO AIDS_NNP and_CC the_DT number_NN of_IN people_NNS in_IN need_NN of_IN ART_NNP ._. The_DT lessons_NNS learned_VBD in_IN the_DT
          industrialized_VBN world_NN have_VBP to_TO be_VB taken_VBN on_IN board_NN ._. The_DT availability_NN of_IN treatment_NN and_CC the_DT
          shift_NN in_IN focus_NN away_RB from_IN very_RB effective_JJ prevention_NN programs_NNS has_VBZ led_VBN to_TO increases_NNS in_IN
          unsafe_JJ sexual_JJ behavior_NN ,_, STIs_NNP ,_, and_CC HIV_NNP transmission_NN in_IN some_DT settings_NNS [_NN 9_CD ,_, 10_CD ,_, 11_CD ]_NN ._. There_EX is_VBZ
          no_DT doubt_NN that_IN effective_JJ therapy_NN can_MD extend_VB and_CC improve_VB the_DT quality_NN of_IN life_NN for_IN those_DT who_WP
          are_VBP treated_VBN ,_, but_CC it_PRP also_RB must_MD be_VB integrated_VBN into_IN a_DT comprehensive_JJ community_NN response_NN to_TO
          HIV_NNP so_IN that_IN it_PRP can_MD enhance_VB the_DT effectiveness_NN of_IN prevention_NN efforts_NNS ._. Long-term_JJ ,_, sustained_VBN
          progress_NN in_IN the_DT fight_NN against_IN AIDS_NNP demands_NNS more_JJR than_IN an_DT exclusive_JJ focus_NN on_IN either_DT
          prevention_NN or_CC treatment_NN alone_RB ._. Prevention_NNP makes_VBZ treatment_NN affordable_JJ ,_, and_CC treatment_NN can_MD
          make_VB prevention_NN more_RBR effective_JJ ._.
          Countries_NNS in_IN sub-_NN Saharan_NNP Africa_NNP are_VBP faced_VBN with_IN the_DT most_RBS devastating_JJ epidemic_NN of_IN our_PRP$
          times_NNS ._. We_PRP now_RB have_VBP the_DT unique_JJ opportunity_NN to_TO derive_VB the_DT maximum_NN impact_NN from_IN available_JJ
          resources_NNS ._. The_DT results_NNS from_IN our_PRP$ analyses_NNS show_VBP how_WRB potential_JJ synergies_NNS between_IN prevention_NN
          and_CC treatment_NN could_MD be_VB translated_VBN into_IN considerable_JJ health_NN benefits_NNS at_IN the_DT population_NN
          level_NN ._. But_CC synergies_NNS do_VBP not_RB mean_VB simply_RB that_DT prevention_NN and_CC treatment_NN are_VBP pursued_VBN in_IN
          parallel_NN ._. When_WRB whole_JJ communities_NNS become_VBP involved_VBN in_IN the_DT scale-up_JJ of_IN treatment_NN access—as_NNS
          will_MD be_VB necessary_JJ to_TO achieve_VB the_DT ambitious_JJ treatment_NN targets_NNS defined_VBN by_IN the_DT 3_CD by_IN 5_CD
          campaign—crucial_NN opportunities_NNS can_MD be_VB created_VBN for_IN increasing_VBG their_PRP$ involvement_NN in_IN
          prevention_NN activities_NNS ._. Only_RB if_IN interactions_NNS with_IN patients_NNS ,_, family_NN ,_, and_CC community_NN members_NNS
          occasioned_JJ by_IN the_DT provision_NN of_IN treatment_NN are_VBP also_RB used_VBN to_TO reinforce_VB prevention_NN ,_, and_CC only_RB
          if_IN prevention_NN workers_NNS have_VBP an_DT opportunity_NN to_TO refer_VB those_DT in_IN need_VBP to_TO care_VB and_CC treatment_NN ,_,
          will_MD we_PRP move_VBP at_IN last_JJ from_IN slogans_NNS to_TO impact_VB ._.
        
      
      
        Supporting_VBG Information_NNP
      
    
  
